Selecta Biosciences Investor Relations Material
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company uses its proprietary Emulate(TM) technology to develop novel therapeutics that target receptors with high specificity for desired cellular targets as well as generate broad-spectrum immune suppression. Selecta Biosciences' wholly owned subsidiary is Emulate Biosciences Corporation, which was founded in 2003 to develop drug discovery technologies based on systems biology principles. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Key slides for Selecta Biosciences Inc
Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023
The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
🇺🇸 United States